↓ Skip to main content

Cochrane Database of Systematic Reviews

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

Overview of attention for article published in Cochrane database of systematic reviews, October 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters
wikipedia
1 Wikipedia page

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
97 Mendeley
Title
Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer
Published in
Cochrane database of systematic reviews, October 2013
DOI 10.1002/14651858.cd010482.pub2
Pubmed ID
Authors

Lawrie, Theresa A, Rabbie, Roy, Thoma, Clemens, Morrison, Jo, Theresa A Lawrie, Roy Rabbie, Clemens Thoma, Jo Morrison

Abstract

Epithelial ovarian cancer (EOC) is often diagnosed at an advanced stage, requiring primary cytoreductive surgery and combination chemotherapy for its first-line management. Currently, the recommended standard first-line chemotherapy is platinum-based, usually consisting of carboplatin and paclitaxel (PAC/carbo). Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin that is associated with fewer and less severe side effects than are seen with non-modified doxorubicin. In combination with carboplatin, PLD has recently been shown to improve progression-free survival compared with PAC/carbo in women with relapsed, platinum-sensitive EOC. It is therefore important to know whether any survival benefit can be attributed to PLD when it is used in the first-line setting.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Canada 1 1%
Unknown 95 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 15 15%
Student > Ph. D. Student 14 14%
Researcher 13 13%
Student > Master 12 12%
Student > Postgraduate 6 6%
Other 15 15%
Unknown 22 23%
Readers by discipline Count As %
Medicine and Dentistry 37 38%
Nursing and Health Professions 9 9%
Pharmacology, Toxicology and Pharmaceutical Science 7 7%
Psychology 5 5%
Biochemistry, Genetics and Molecular Biology 3 3%
Other 10 10%
Unknown 26 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 March 2020.
All research outputs
#5,234,516
of 17,362,547 outputs
Outputs from Cochrane database of systematic reviews
#7,715
of 11,660 outputs
Outputs of similar age
#57,044
of 194,186 outputs
Outputs of similar age from Cochrane database of systematic reviews
#62
of 103 outputs
Altmetric has tracked 17,362,547 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 11,660 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.0. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,186 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 103 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.